Special Issue

West Nile Virus 2019

Message from the Guest Editor

West Nile virus (WNV) is the most widespread flavivirus present in all continents, except Antarctica. It is also a truly emerging virus, which 20 years ago was absent in the Americas and had little impact in Europe. This changed significantly when lineage 1 WNV was introduced to the United States in 1999, followed by the emergence of two different lineage 2 WNVs in Europe around 2004. After an adaptation period of a few years, the newly introduced viruses spread quickly across the Americas and Europe. Humans, horses, and birds have been confirmed to be susceptible hosts for WNV, with clinical symptoms ranging from mild to life-threatening neuro-invasive West Nile disease, In 2018, Europe experienced an upsurge in the number of WNV infections. Similarly, in the U.S., more human cases were seen in 2018 when compared to the previous year(s). The natural transmission cycle of WNV involves certain mosquito species, mainly *Culex*, and a number of avian species. Since transmission-competent mosquito species are abundantly found in cooler climatic regions, further dispersal of the virus is likely.

Guest Editor

Prof. Dr. Norbert Nowotny

 Viral Zoonoses, Emerging and Vector-Borne Infections Group, Institute of Virology, University of Veterinary Medicine, Vienna, Austria
 College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates

Deadline for manuscript submissions

closed (31 December 2019)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/22950

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).